Interview 29 Nov 2022
LAG-3: The next big checkpoint inhibitor target
Since their first approval a decade ago, immune checkpoint inhibitors have been gaining momentum in the treatment of cancer. The Australian-French firm Immutep explains why the immune checkpoint target LAG-3…
